Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biological therapy for psoriatic arthritis in clinical practice: outcomes up to 2 years.
Virkki LM, Sumathikutty BC, Aarnio M, Valleala H, Heikkilä R, Kauppi M, Karstila K, Pirilä L, Ekman P, Salomaa S, Romu M, Seppälä J, Niinisalo H, Konttinen YT, Nordström DC. Virkki LM, et al. Among authors: valleala h. J Rheumatol. 2010 Nov;37(11):2362-8. doi: 10.3899/jrheum.091477. Epub 2010 Aug 17. J Rheumatol. 2010. PMID: 20716655
Outcomes of switching anti-TNF drugs in rheumatoid arthritis--a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN).
Virkki LM, Valleala H, Takakubo Y, Vuotila J, Relas H, Komulainen R, Koivuniemi R, Yli-Kerttula U, Mali M, Sihvonen S, Krogerus ML, Jukka E, Nyrhinen S, Konttinen YT, Nordström DC. Virkki LM, et al. Among authors: valleala h. Clin Rheumatol. 2011 Nov;30(11):1447-54. doi: 10.1007/s10067-011-1779-1. Epub 2011 Jun 7. Clin Rheumatol. 2011. PMID: 21644062
Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial.
Hakala M, Kröger H, Valleala H, Hienonen-Kempas T, Lehtonen-Veromaa M, Heikkinen J, Tuomiranta T, Hannonen P, Paimela L; ONCE trial group. Hakala M, et al. Among authors: valleala h. Scand J Rheumatol. 2012 Aug;41(4):260-6. doi: 10.3109/03009742.2012.664647. Scand J Rheumatol. 2012. PMID: 22803768 Clinical Trial.
Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy.
Aaltonen KJ, Joensuu JT, Virkki L, Sokka T, Aronen P, Relas H, Valleala H, Rantalaiho V, Pirilä L, Puolakka K, Uusitalo T, Blom M, Konttinen YT, Nordström D. Aaltonen KJ, et al. Among authors: valleala h. J Rheumatol. 2015 Mar;42(3):372-8. doi: 10.3899/jrheum.140853. Epub 2015 Jan 15. J Rheumatol. 2015. PMID: 25593230
39 results